Key findings in HHT patients include the identification of somatic mutations in AVMs that lead to bi-allelic LOF in ACVRL1 or ENG15, and the observation that the anti-VEGFA antibody bevacizumab has possible therapeutic value in HHT 16,17. Here, ACVRL1 is linked to hereditary hemorrhagic telangiectasia.